Previous 10 | Next 10 |
2024-05-13 05:18:05 ET Summary Intellia's longstanding collaboration with Regeneron is important in its value proposition. With three cutting-edge late-stage programs, NTLA is among the top tier of gene editing companies. Solid financials underpin the Company. Intellia pre...
2024-05-12 23:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...
2024-05-09 11:39:11 ET Intellia Therapeutics, Inc. (NTLA) Q1 2024 Results Conference Call May 9, 2024 08:00 AM ET Company Participants Ian Karp - Senior Vice President of Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David...
2024-05-09 09:32:14 ET Summary Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales. Casgevy is approved to treat Sickle Cell Disease and Trans...
2024-05-09 07:32:40 ET More on Intellia Therapeutics Intellia Therapeutics Is On The Move Intellia opts out of hemophilia pact with Regeneron Seeking Alpha’s Quant Rating on Intellia Therapeutics Read the full article on Seeking Alpha For furth...
Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy Aligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy, subject to...
2024-05-08 11:35:46 ET More on Intellia Therapeutics Intellia Therapeutics Is On The Move Intellia Therapeutics, Inc. (NTLA) Q4 2023 Earnings Call Transcript Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier Intellia opts out of...
2024-05-03 14:18:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene editing stocks are among the most intriguing in the biotech scene. The genomics revolution may be as exciting as the ongoing artificial intelligence one. But, of course, only time will tel...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a confer...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
2024-07-13 10:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...